Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: A cross sectional study

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Piloya, Thereza ^a   Bakeera Kitaka, Sabrina ^a   Kekitiinwa, Adeodata ^b   Kamya, Moses R ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b MULAGO HOSPITAL   (Uganda)

Author keywords

Children; Fat redistribution; Highly active antiretroviral therapy; Human immunodeficiency virus; Hyperlipidemia; Lipodystrophy; Metabolic abnormalities

Indexed keywords

ANTIRETROVIRUS AGENT; GLUCOSE; LIPID; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BODY FAT DISTRIBUTION; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; UGANDA; BLOOD; HIV ASSOCIATED LIPODYSTROPHY; METHODOLOGY; QUESTIONNAIRE;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPIDS; MALE; QUESTIONNAIRES; RISK FACTORS; UGANDA;

EID: 84867469771     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17427     Document Type: Article

References (26)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-30.
2. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet. 2001;358:1322-7. (Pubitemid 33016496)
3. Leonard EG, McComsey AG. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003;22:77-84. (Pubitemid 36091782)
4. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-10. (Pubitemid 34532934)
5. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet. 1999;353:1243-4. (Pubitemid 29168470)
6. Viganò A, Thorne C, Brambilla P, Newell ML. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-51. (Pubitemid 38925137)
7. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164: 271-6. (Pubitemid 40613041)
8. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr. 2007;166:13-21. (Pubitemid 44900517)
9. Innes S, Leon L, Cotton M. Lipodystrophy syndrome in HIV infected children on HAART. South Afr J HIV Med. 2009:76-80.
10. Ministry of Health, Uganda. National antiretroviral treatment and care guidelines for adults and children. Kampala: Ministry of health, Uganda; 2008.
11. UNAIDS/WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision [cited 2008 August 15]. Available from: http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf Geneva, 2006.
12. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
13. El-Sadr W, Reiss P, De Wit S. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age and lipid changes. 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, USA. (Abstract 42)
14. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31 Suppl 3:140-4.
15. Dart Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123-31.
16. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-9. (Pubitemid 29278477)
17. Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J. 2006;25(5):427-31.
18. María RM, Noris P. Fat redistribution and metabolic disturbances in HIV-infected children and adolescents under highly active antiretroviral therapy (HAART). Bol Med Hosp Infant Mex. 2009 July-Aug;66:41-6.
19. Vigano A, Thorne C. European Collaborative Study. Italian register on HIV in children. Fat redistribution and metabolic abnormalities in HIV-infected children and adolescents in Europe. 10th Conference on Retroviruses and Opportunistic infections; February 2003; Boston. (Abstract 774)
20. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected Children. J Acquir Immune Defic Syndr. 2005;40:161-8. (Pubitemid 41395714)
21. US Preventive Services Task Force. Screening for lipid disorders in children, recommendation statement. Pediatrics. 2007;120:e215-9.
22. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123-8.
23. Carr A, Miller J, Law M, Cooper D. A syndrome of lipodystrophy (LD), lactic acidemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: a contribution to PI-related LD syndrome. Antiviral Ther. 1999;4(2):19-20.
24. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2000;16:2447-54. (Pubitemid 35471693)
25. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. Journal of the International AIDS Society. 2010;13(31).
26. Spoulou V, Kanaka-Gantenbein C, Bathrellou I, Mora S, Mostrou G, Sidossis L, et al. Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. Hormones. 2011;10(2): 149-55.